Public COA audit

Semaglutide

Audited July 28, 2026

Evidence suggests fabrication

Multiple signals on this document conflict with known lab formats or verification patterns.

Legitimacy
15
Confidence
92%
Panels
4/7
Purity (printed)
99.9%

Document details

Fields extracted from the certificate — not order or payment data.

Batch / lot
SEMA10-0616
Identity method
MALDI-MS
Sample date
2026-06-19
Issue date
2026-06-25

7-panel checklist

Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.

4 of 7 present · 4 passed · 0 failed · 0 reported · 3 missing

Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.

  • Identity

    Tested · passed · core

    Compound identity confirmed (e.g. HPLC, mass spec).

    Semaglutide

  • Purity

    Tested · passed · core

    Reported purity percentage for the analyte.

    99.9%

  • Heavy metals

    Tested · passed

    Lead, arsenic, cadmium, mercury, or similar limits.

    <0.01 ppm

  • Microbial

    Not on this COA

    Bioburden / microbial limits testing.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Endotoxin

    Tested · passed · core

    LAL or chromogenic endotoxin assay.

    <0.05 EU/mL

  • Sterility

    Not on this COA

    Sterility testing where applicable.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Residual solvent / water

    Not on this COA

    Residual solvents or water content limits.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

How to read this

Had data · good

Panel present with a pass (or clear acceptance).

Had data · bad

Panel present with a fail — a concrete quality signal.

Had data · unclear

Value reported without an explicit pass/fail mark.

Missing

Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.

Findings

Evidence-linked observations from this audit.

  • Future dates (2026)

    Sample received June 19, 2026 and COA issued June 25, 2026 — both dates are in the future, which is impossible for a legitimate document created in 2024 or earlier

  • Unverifiable testing laboratory

    Bioviridian does not appear to be a known or established analytical testing laboratory for peptides. The URL bioviridians.com cannot be verified as a legitimate testing facility

  • Product image watermark mismatch

    The HPLC chromatogram contains an 'American Peptides' logo/watermark, but the vendor is listed as 'American Peptides' and the testing lab is 'Bioviridian' — suggests possible mixing of vendor marketing materials with purported independent testing

  • Suspiciously perfect purity

    99.9% purity is exceptionally high and at the upper limit of what is typically achievable; while possible, this combined with other red flags raises concern

  • Mass spectrum shows single peak

    The mass spectrum shows molecular weight 4115.683 [M+H]+ which is close to expected semaglutide MW (4113.6 listed), but the extremely clean single peak with no impurities is unusual for a real sample

  • Batch number present

    Lot number SEMA10-0616 is clearly stated

  • Missing microbial and sterility testing

    No microbial contamination or sterility testing reported, which would typically be included for pharmaceutical-grade peptides

PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.